Overview Dividends

(APLS) Apellis Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03753U1060

Therapeutic, Complement, Hemoglobinuria, Macular Degeneration

EPS (Earnings per Share)

EPS (Earnings per Share) of APLS over the last years for every Quarter: "2020-09": -1.79, "2020-12": 0.93, "2021-03": -2.32, "2021-06": -2.72, "2021-09": -2.28, "2021-12": -1.61, "2022-03": -1.42, "2022-06": -1.46, "2022-09": -1.75, "2022-12": -1.5, "2023-03": -1.56, "2023-06": -1.02, "2023-09": -1.17, "2023-12": -0.73, "2024-03": -0.42, "2024-06": -0.28, "2024-09": -0.4624, "2024-12": -0.29, "2025-03": -0.74, "2025-06": -0.33, "2025-09": 1.67,
EPS Growth (3y CAGR): 221.16%
EPS Trend (3y Corr): 78.7%
Last SUE: 0.43σ
Qual. Beats: 0

Revenue

Revenue of APLS over the last years for every Quarter: 2020-09: 0.646, 2020-12: 250, 2021-03: 0, 2021-06: 0.623, 2021-09: 5.65, 2021-12: 60.29, 2022-03: 14.381, 2022-06: 16.322, 2022-09: 22.056, 2022-12: 22.663, 2023-03: 44.846, 2023-06: 94.969, 2023-09: 110.399, 2023-12: 146.377, 2024-03: 172.325, 2024-06: 199.685, 2024-09: 196.83, 2024-12: 212.528, 2025-03: 166.797, 2025-06: 178.494, 2025-09: 458.578,
Revenue Growth (3y CAGR): 198.50%
Revenue Trend (3y Corr): 86.6%
Last SUE: 3.41σ
Qual. Beats: 1
Risk via 10d forecast
Volatility 69.4%
Value at Risk 5%th 91.1%
Relative Tail Risk -20.25%
Reward TTM
Sharpe Ratio -0.35
Alpha -37.09
Character TTM
Hurst Exponent 0.528
Beta 0.930
Beta Downside 1.365
Drawdowns 3y
Max DD 82.47%
Mean DD 49.21%
Median DD 57.56%

Description: APLS Apellis Pharmaceuticals November 09, 2025

Apellis Pharmaceuticals (NASDAQ: APLS) is a commercial-stage biopharma that develops complement-inhibiting therapeutics for high-unmet-need diseases, leveraging its proprietary pegylated C3 inhibitor platform.

Its flagship products are EMPAVELI (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH) and SYFOVRE for geographic atrophy (GA) secondary to age-related macular degeneration, both of which have received FDA approval and are generating commercial revenue.

The company is expanding EMPAVELI’s label to include several complement-mediated renal disorders (e.g., C3 glomerulopathy, immune-complex MPGN) and is advancing APL-3007, an siRNA therapy, as a next-generation GA candidate.

Strategic collaborations include a long-term license with Swedish Orphan Biovitrum (SOBI) for pegcetacoplan commercialization and a partnership with Beam Therapeutics to apply base-editing technology to complement-driven indications.

Key metrics as of Q3 2024: $215 million in total revenue (≈ 70 % from EMPAVELI), cash and equivalents of $540 million, and an upcoming FDA decision on APL-3007 slated for Q1 2025; the GA market is projected to exceed $5 billion by 2028, driven by an aging global population and increasing AMD prevalence.

For a deeper dive into APLS’s valuation metrics and risk profile, the ValueRay platform offers a concise analyst toolkit.

APLS Stock Overview

Market Cap in USD 2,506m
Sub-Industry Biotechnology
IPO / Inception 2017-11-09
Return 12m vs S&P 500 -36.5%
Analyst Rating 4.09 of 5

APLS Dividends

Currently no dividends paid

APLS Growth Ratios

Metric Value
CAGR 3y -27.57%
CAGR/Max DD Calmar Ratio -0.33
CAGR/Mean DD Pain Ratio -0.56
Current Volume 2275.3k
Average Volume 2517.1k

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income (45.0m TTM) > 0 and > 6% of Revenue (6% = 61.0m TTM)
FCFTA 0.07 (>2.0%) and ΔFCFTA 30.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 69.97% (prev 89.85%; Δ -19.88pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.07 (>3.0%) and CFO 78.9m > Net Income 45.0m (YES >=105%, WARN >=100%)
Net Debt (-364.9m) to EBITDA (93.4m) ratio: -3.91 <= 3.0 (WARN <= 3.5)
Current Ratio 3.54 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (126.0m) change vs 12m ago 1.71% (target <= -2.0% for YES)
Gross Margin 88.80% (prev 86.34%; Δ 2.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 103.7% (prev 79.30%; Δ 24.38pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 2.04 (EBITDA TTM 93.4m / Interest Expense TTM 45.0m) >= 6 (WARN >= 3)

Altman Z'' -8.78

(A) 0.67 = (Total Current Assets 990.7m - Total Current Liabilities 279.5m) / Total Assets 1.06b
(B) -2.79 = Retained Earnings (Balance) -2.95b / Total Assets 1.06b
warn (B) unusual magnitude: -2.79 — check mapping/units
(C) 0.09 = EBIT TTM 91.7m / Avg Total Assets 980.3m
(D) -4.50 = Book Value of Equity -2.96b / Total Liabilities 657.6m
Total Rating: -8.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.95

1. Piotroski 5.50pt
2. FCF Yield 3.67%
3. FCF Margin 7.74%
4. Debt/Equity 0.28
5. Debt/Ebitda -3.91
6. ROIC - WACC (= 3.77)%
7. RoE 18.94%
8. Rev. Trend 86.55%
9. EPS Trend 78.70%

What is the price of APLS shares?

As of November 21, 2025, the stock is trading at USD 19.54 with a total of 2,275,289 shares traded.
Over the past week, the price has changed by -1.36%, over one month by -27.82%, over three months by -26.49% and over the past year by -28.92%.

Is APLS a buy, sell or hold?

Apellis Pharmaceuticals has received a consensus analysts rating of 4.09. Therefore, it is recommended to buy APLS.
  • Strong Buy: 10
  • Buy: 4
  • Hold: 8
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the APLS price?

Issuer Target Up/Down from current
Wallstreet Target Price 35.4 81.1%
Analysts Target Price 35.4 81.1%
ValueRay Target Price 16.8 -14.3%

APLS Fundamental Data Overview November 15, 2025

Market Cap USD = 2.51b (2.51b USD * 1.0 USD.USD)
P/E Trailing = 55.0278
P/E Forward = 46.2963
P/S = 2.466
P/B = 6.3142
Beta = 0.359
Revenue TTM = 1.02b USD
EBIT TTM = 91.7m USD
EBITDA TTM = 93.4m USD
Long Term Debt = 361.1m USD (from longTermDebt, last quarter)
Short Term Debt = 100.6m USD (from shortTermDebt, last quarter)
Debt = 114.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -364.9m USD (from netDebt column, last quarter)
Enterprise Value = 2.14b USD (2.51b + Debt 114.3m - CCE 479.2m)
Interest Coverage Ratio = 2.04 (Ebit TTM 91.7m / Interest Expense TTM 45.0m)
FCF Yield = 3.67% (FCF TTM 78.6m / Enterprise Value 2.14b)
FCF Margin = 7.74% (FCF TTM 78.6m / Revenue TTM 1.02b)
Net Margin = 4.43% (Net Income TTM 45.0m / Revenue TTM 1.02b)
Gross Margin = 88.80% ((Revenue TTM 1.02b - Cost of Revenue TTM 113.8m) / Revenue TTM)
Gross Margin QoQ = 94.65% (prev 92.12%)
Tobins Q-Ratio = 2.02 (Enterprise Value 2.14b / Total Assets 1.06b)
Interest Expense / Debt = 9.87% (Interest Expense 11.3m / Debt 114.3m)
Taxrate = 0.28% (602.0k / 216.3m)
NOPAT = 91.4m (EBIT 91.7m * (1 - 0.28%))
Current Ratio = 3.54 (Total Current Assets 990.7m / Total Current Liabilities 279.5m)
Debt / Equity = 0.28 (Debt 114.3m / totalStockholderEquity, last quarter 401.2m)
Debt / EBITDA = -3.91 (Net Debt -364.9m / EBITDA 93.4m)
Debt / FCF = -4.64 (Net Debt -364.9m / FCF TTM 78.6m)
Total Stockholder Equity = 237.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.25% (Net Income 45.0m / Total Assets 1.06b)
RoE = 18.94% (Net Income TTM 45.0m / Total Stockholder Equity 237.6m)
RoCE = 15.32% (EBIT 91.7m / Capital Employed (Equity 237.6m + L.T.Debt 361.1m))
RoIC = 13.23% (NOPAT 91.4m / Invested Capital 691.3m)
WACC = 9.46% (E(2.51b)/V(2.62b) * Re(9.44%) + D(114.3m)/V(2.62b) * Rd(9.87%) * (1-Tc(0.00)))
Discount Rate = 9.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.96%
[DCF Debug] Terminal Value 69.58% ; FCFE base≈78.6m ; Y1≈64.5m ; Y5≈46.1m
Fair Price DCF = 5.33 (DCF Value 674.4m / Shares Outstanding 126.5m; 5y FCF grow -21.61% → 3.0% )
EPS Correlation: 78.70 | EPS CAGR: 221.2% | SUE: 0.43 | # QB: 0
Revenue Correlation: 86.55 | Revenue CAGR: 198.5% | SUE: 3.41 | # QB: 1

Additional Sources for APLS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle